Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)
KemPharm team provided development and regulatory services to Corium pursuant to a master development services agreement CELEBRATION, Fla. , March 16, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH) (the Company, or KemPharm ), a specialty pharmaceutical company focused on the discovery
Toggle Summary KemPharm to Report Fourth Quarter and Full-Year 2021 Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, March 30, 2022 , 5:00 p.m. ET CELEBRATION, Fla. , March 10, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla. , Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today
Toggle Summary KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy
KemPharm to Advance KP1077 for Idiopathic Hypersomnia as Lead SDX Product Candidate Strong Balance Sheet with Cash and Cash Equivalents of $127.8M as of December 31, 2021 ; Available Cash and Revenues Extend Cash Runway through 2025 and Beyond AZSTARYS ® National Launch Accelerating, Full Sales
Toggle Summary KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Wednesday, January 19, 2022 at 4:30 p.m. ET CELEBRATION, Fla. , Jan. 12, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Announces Research Involving Serdexmethylphenidate to be Featured in Two Poster Presentations at the APSARD 2022 Annual Conference
Data highlight key pharmacokinetic properties of serdexmethylphenidate that are instrumental to its consistent and smooth release of d-MPH CELEBRATION, Fla. , Jan. 11, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and
Toggle Summary KemPharm to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2022”
CELEBRATION, Fla. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today the company is participating in BIO Partnering @ JPM, which is being held virtually alongside
Toggle Summary KemPharm, Inc. Announces Authorization of $50 Million Share Repurchase Program
CELEBRATION, Fla. , Dec. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today its Board of Directors has authorized a program to repurchase up to $50 million of the
Toggle Summary KemPharm, Inc. Announces Top-Line Results from Clinical Trial Evaluating the Safety and Pharmacokinetics of “Higher-Dose SDX”
Data reveal serdexmethylphenidate (SDX) delivered at doses higher than those studied with AZSTARYS ® is well-tolerated, yields dose-proportional d-MPH exposure, and produces targeted biological effects CELEBRATION, Fla. , Dec. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty
Toggle Summary KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021
CELEBRATION, Fla. , Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc.  (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced its common stock has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) in accordance